Risk factors affecting seroconversion after influenza A/H1N1 vaccination in hemodialysis patients

BMC Nephrol. 2012 Dec 3:13:165. doi: 10.1186/1471-2369-13-165.

Abstract

Background: Hemodialysis (HD) patients have multiple causes of immune dysfunction and poor immune response to influenza vaccination. We investigated the antibody response rate to a pandemic H1N1/2009 influenza vaccination and clinical parameters influencing the induction of antibody responses in HD patients.

Methods: A total of 114 HD patients were vaccinated with a monovalent adjuvanted H1N1 inactivated influenza vaccine. Titers of neutralizing antibodies were evaluated by hemagglutination inhibition (HI) assay at pre- and 4 weeks after vaccination. Seroconversion was defined as either a pre-vaccination HI titer < 1:10 and a post vaccination HI titer > 1:40 or a pre-vaccination HI titer ≥ 1:10 and a minimum four-fold rise in post-vaccination HI antibody titer. Seventeen out of 114 HD patients (14.9%) tested positive for antibodies against influenza A/H1N1/2009 before vaccination. The remaining 97 baseline sero-negative patients were included in the analysis.

Results: Only 30 (30.9%) HD patients had seroconversion 4 weeks after vaccination. The elderly patients, those over 65 years of age, showed significantly lower seroconversion rate compared to younger HD patients (20.5% vs. 39.6%, p = 0.042). Furthermore, patients with hemoglobin values less than 10 g/dL had a significantly lower seroconversion rate compared to those with higher hemoglobin values (20.0 vs. 38.6%, p = 0.049). By multivariate logistic regression analysis, only age ≥65 years (OR = 0.336, 95% confidence interval (CI) 0.116-0.971, p = 0.044) and hemoglobin levels <10 g/dL (OR = 0.315, 95% CI 0.106-0.932, p = 0.037) were independently associated with seroconversion after vaccination.

Conclusions: Our data show that HD patients, especially who are elderly with low hemoglobin levels, are at increased risk for lower seroconversion rate after influenza A/H1N1 vaccination. Further studies are needed to improve the efficacy of vaccination in these high risk patients.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Viral / blood*
  • Comorbidity
  • Female
  • Humans
  • Influenza A Virus, H1N1 Subtype*
  • Influenza Vaccines / therapeutic use*
  • Influenza, Human / epidemiology
  • Influenza, Human / immunology
  • Influenza, Human / prevention & control*
  • Kidney Failure, Chronic / epidemiology
  • Kidney Failure, Chronic / immunology*
  • Kidney Failure, Chronic / rehabilitation*
  • Male
  • Mass Vaccination / statistics & numerical data
  • Middle Aged
  • Prevalence
  • Renal Dialysis / statistics & numerical data*
  • Republic of Korea / epidemiology
  • Risk Factors
  • Treatment Outcome

Substances

  • Antibodies, Viral
  • Influenza Vaccines